Adenosine in the management of supraventricular tachycardia in children

J Paediatr Child Health. 1998 Feb;34(1):53-6. doi: 10.1046/j.1440-1754.1998.00153.x.

Abstract

Objective: To assess the efficacy and safety of adenosine in the management of supraventricular tachycardia in children.

Methodology: A review of 43 children with supraventricular tachycardia who received intravenous adenosine between June 1992 and July 1995.

Results: Thirty-five patients had re-entrant supraventricular tachycardia and eight patients had atrial tachydysrhythmias. Reversion to sinus rhythm occurred in 75% of episodes in all patients treated for supraventricular tachycardia, and in 96% of episodes in patients with re-entrant supraventricular tachycardia. Early re-initiation of supraventricular tachycardia after reversion to sinus rhythm occurred in 25% of episodes. Sixteen percent of patients reverted with the recommended 0.05 mg/kg starting dose, and 35% reverted with a dose of 0.1 mg/kg. Four patients were given adenosine as a diagnostic procedure to elicit occult pre-excitation. The most common side effects were brief feelings of discomfort. No serious side effects occurred.

Conclusion: Adenosine is safe and effective in the management of supraventricular tachycardia in children. A commencing dose of 0.1 mg/kg is appropriate.

MeSH terms

  • Adenosine / administration & dosage
  • Adenosine / therapeutic use*
  • Adolescent
  • Anti-Arrhythmia Agents / administration & dosage
  • Anti-Arrhythmia Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Tachycardia, Supraventricular / drug therapy*
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents
  • Adenosine